Giant gains for Hologic; Smith & Nephew held back by DoJ probe
This article was originally published in Clinica
Executive Summary
Cardiac ablation specialist AtriCure succeeded in narrowing its loss by 17% on the back of healthy gains in revenue. The West Chester, Ohio-based firm's top-line was boosted by a 28% increase in sales of its minimally-invasive products and a 22% increase in sales of its open-heart technology in the US. However, these gains were outweighed by research and development costs, and administrative expenses, resulting in an overall loss of $2.6m. AtriCure has narrowed its revenue outlook for 2007 to $48-48.7m and lowered its loss per share forecast to a range of 92-97 cents per share.